NCT05626634 2025-12-03
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
Longboard Pharmaceuticals
Phase 2 Completed
Clinical Trials
5 trialsNCT04485104 2025-10-31
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04106219 2025-07-23
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
Phase 1 Active not recruiting
NCT03731455 2025-07-17
WIN
Wise S.r.l.
Phase NA Completed
NCT02392078 2025-04-24
LAANTERN
Monteris Medical
Completed